Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management

Key Points

• Ritholtz Wealth Management increased its stake in Puma Biotechnology by 47.4% in Q4 to 694,001 shares (about 1.38% ownership) valued at $4.13M, while institutional investors own roughly 61.29% of the stock.
• Puma beat Q4 estimates, reporting EPS of $0.26 vs. $0.24 and revenue of $75.5M vs. $68.6M, with a 13.6% net margin and 27.8% return on equity.
• Shares opened at $7.78 and trade in a one‑year range of $2.68–$7.90; the company has a market cap of about $396M and a P/E of 12.75.

Ritholtz Wealth Management raised its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 47.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 694,001 shares of the biopharmaceutical company's stock after acquiring an additional 223,234 shares during the quarter. Ritholtz Wealth Management owned approximately 1.38% of Puma Biotechnology worth $4,129,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC bought a new position in Puma Biotechnology during the 2nd quarter valued at $36,000. BNP Paribas Financial Markets boosted its stake in Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock valued at $43,000 after acquiring an additional 2,290 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Puma Biotechnology during the 4th quarter valued at $59,000. Caprock Group LLC bought a new position in Puma Biotechnology during the 3rd quarter valued at $59,000. Finally, Perkins Capital Management Inc. bought a new position in Puma Biotechnology during the 3rd quarter valued at $65,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Stock Performance

Puma Biotechnology stock opened at $7.78 on Friday. The firm's 50-day moving average is $6.62 and its 200-day moving average is $5.91. Puma Biotechnology, Inc. has a 1 year low of $2.68 and a 1 year high of $7.90. The company has a market cap of $395.92 million, a P/E ratio of 12.75 and a beta of 1.19.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.02. Puma Biotechnology had a net margin of 13.62% and a return on equity of 27.80%. The company had revenue of $75.50 million for the quarter, compared to the consensus estimate of $68.60 million. As a group, sell-side analysts predict that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analyst Ratings Changes

PBYI has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "hold (c+)" rating on shares of Puma Biotechnology in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 21st. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Puma Biotechnology currently has an average rating of "Hold".

Puma Biotechnology Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.